Novo Nordisk A/S (NYSE:NVO) Shares Sold by RFG Advisory LLC

RFG Advisory LLC cut its stake in Novo Nordisk A/S (NYSE:NVO) by 40.9% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 12,024 shares of the company’s stock after selling 8,304 shares during the period. RFG Advisory LLC’s holdings in Novo Nordisk A/S were worth $1,034,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently modified their holdings of NVO. Financial Partners Group LLC boosted its stake in Novo Nordisk A/S by 31.4% during the 4th quarter. Financial Partners Group LLC now owns 14,384 shares of the company’s stock valued at $1,237,000 after purchasing an additional 3,438 shares during the period. Cornerstone Wealth Management LLC raised its holdings in shares of Novo Nordisk A/S by 26.8% during the fourth quarter. Cornerstone Wealth Management LLC now owns 5,589 shares of the company’s stock valued at $481,000 after buying an additional 1,183 shares during the last quarter. Montecito Bank & Trust boosted its position in shares of Novo Nordisk A/S by 17.1% during the fourth quarter. Montecito Bank & Trust now owns 3,861 shares of the company’s stock worth $332,000 after buying an additional 565 shares during the period. Cerro Pacific Wealth Advisors LLC grew its holdings in Novo Nordisk A/S by 33.5% in the 4th quarter. Cerro Pacific Wealth Advisors LLC now owns 3,301 shares of the company’s stock worth $284,000 after buying an additional 828 shares in the last quarter. Finally, Apeiron RIA LLC increased its position in Novo Nordisk A/S by 25.3% in the 4th quarter. Apeiron RIA LLC now owns 5,935 shares of the company’s stock valued at $510,000 after acquiring an additional 1,199 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

NVO has been the subject of several recent analyst reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. BMO Capital Markets reduced their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Finally, UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Stock Up 8.4 %

NVO stock opened at $87.94 on Friday. The company’s 50 day simple moving average is $95.35 and its 200-day simple moving average is $115.17. Novo Nordisk A/S has a 52-week low of $78.17 and a 52-week high of $148.15. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. The firm has a market capitalization of $394.65 billion, a P/E ratio of 28.46, a P/E/G ratio of 0.90 and a beta of 0.45.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.